Oruka Therapeutics (ORKA) Competitors $15.26 -0.08 (-0.49%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA vs. MESO, DNLI, ADPT, ANIP, CGON, VCEL, SRPT, BEAM, ARQT, and TWSTShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Mesoblast (MESO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), Vericel (VCEL), Sarepta Therapeutics (SRPT), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Its Competitors Mesoblast Denali Therapeutics Adaptive Biotechnologies ANI Pharmaceuticals CG Oncology Vericel Sarepta Therapeutics Beam Therapeutics Arcutis Biotherapeutics Twist Bioscience Mesoblast (NASDAQ:MESO) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment. Do insiders and institutionals hold more shares of MESO or ORKA? 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate MESO or ORKA? Mesoblast presently has a consensus target price of $18.00, suggesting a potential upside of 13.10%. Oruka Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 164.67%. Given Oruka Therapeutics' higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has better earnings and valuation, MESO or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.90M345.27-$87.96MN/AN/AOruka TherapeuticsN/AN/A-$83.72M-$2.81-5.43 Is MESO or ORKA more profitable? Mesoblast's return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Oruka Therapeutics N/A -26.26%-24.16% Does the media refer more to MESO or ORKA? In the previous week, Oruka Therapeutics had 4 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Oruka Therapeutics and 7 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.99 beat Oruka Therapeutics' score of 0.56 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, MESO or ORKA? Mesoblast has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500. SummaryOruka Therapeutics beats Mesoblast on 6 of the 11 factors compared between the two stocks. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$571.30M$2.46B$5.59B$9.82BDividend YieldN/A1.68%4.60%4.11%P/E Ratio-5.4321.9930.2125.67Price / SalesN/A683.80448.53106.03Price / CashN/A183.0237.7558.93Price / Book1.684.718.436.01Net Income-$83.72M$31.61M$3.26B$264.94M7 Day Performance11.59%3.65%3.90%2.65%1 Month Performance3.78%3.03%4.16%1.49%1 Year PerformanceN/A13.41%35.99%29.16% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics2.9341 of 5 stars$15.26-0.5%$40.38+164.7%N/A$571.30MN/A-5.43N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMESOMesoblast1.5489 of 5 stars$15.00+2.0%$18.00+20.0%+140.7%$1.92B$5.90M0.0080Gap UpDNLIDenali Therapeutics4.2729 of 5 stars$13.03-6.4%$33.85+159.8%-35.7%$1.90B$330.53M-4.91430News CoverageEarnings ReportAnalyst RevisionGap DownADPTAdaptive Biotechnologies2.6139 of 5 stars$12.38+1.9%$12.380.0%+185.1%$1.88B$178.96M-15.08790Gap DownANIPANI Pharmaceuticals3.2548 of 5 stars$86.55+2.0%$84.75-2.1%+50.5%$1.88B$614.38M-112.87600Earnings ReportAnalyst ForecastCGONCG Oncology1.4265 of 5 stars$24.46+2.2%$55.30+126.1%-20.9%$1.87B$1.14M-13.8361Earnings ReportAnalyst RevisionVCELVericel2.3694 of 5 stars$36.59+3.3%$60.33+64.9%-17.5%$1.85B$237.22M305.78300Positive NewsSRPTSarepta Therapeutics4.6076 of 5 stars$17.97+0.2%$44.17+145.7%-84.7%$1.76B$1.90B-20.691,372Trending NewsShort Interest ↑Gap UpBEAMBeam Therapeutics2.2605 of 5 stars$16.99-1.0%$48.45+185.1%-28.0%$1.73B$63.52M-3.79510Gap UpARQTArcutis Biotherapeutics2.4746 of 5 stars$14.23+0.3%$19.80+39.1%+57.1%$1.70B$196.54M-18.96150Analyst RevisionGap DownTWSTTwist Bioscience3.9383 of 5 stars$27.74+0.4%$49.40+78.1%-35.7%$1.67B$312.97M-19.10990 Related Companies and Tools Related Companies MESO Competitors DNLI Competitors ADPT Competitors ANIP Competitors CGON Competitors VCEL Competitors SRPT Competitors BEAM Competitors ARQT Competitors TWST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.